A Slow Economy and High Development Costs to Drive Rise in Pharmaceutical Outsourcing to Contract Research Organizations
FARMINGTON, Conn., Aug. 22, 2012 /PRNewswire-iReach/ — It’s a well known data point that while the pills a doctor prescribes may cost pennies each to manufacture, the first pill cost many millions of dollars to research, develop, test, and certify. Along the way, many routes are pursued and ultimately dropped when they fail to yield marketable results. One way drug manufacturers can lower their costs and increase their output is to outsource stages of the process to Contract Research Organizations (CROs) that specialize in drug discovery, hit confirmation, and lead optimization.
Global Information Inc, in cooperation with its premium market research publishing partners, is pleased to announce three new market research reports exploring the market for CROs, providing valuable data for market participants – both CROs and pharmaceutical companies themselves – as well as investors, reporters, analysts, and regulators.
Contract Research Organization Market in the US 2011-2015
TechNavio’s analysts forecast the Pharmaceutical Contract Research Organization market in the US will grow at a CAGR of 9.7 percent between 2011 and 2015. One of the key factors contributing to this is the increasing outsourcing of R&D activities. The CRO market in the US has also been witnessing the trend of emerging outsourcing destinations. However, the shortage of CRO staff could pose a challenge to the growth of this market.
TechNavio’s report, The Contract Research Organization Market in the US 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the USA region; it also covers the Contract Research Organization market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Charles River Laboratories International Inc., Covance Inc., Pharmaceutical Product Development Inc., Quintiles Transnational Corp.
An Executive Summary, table of contents, and free sample are available from GII at http://www.giiresearch.com/report/infi248653-contract-research-organization-market-us.html
Medical Devices Contract Research Organizations – Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018
GlobalData’s new market research report, Medical Devices Contract Research Organizations – Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018, provides key data, information and analysis on the global medical devices CRO market. This report outlines the current market and competitive landscapes, gives market trend information for the medical devices CRO market, and provides comprehensive information on the key trends affecting the market, as well as key analytical content. The report also reviews the competitive landscape and technology offerings.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
An Executive Summary of this analysis, full table of contents, and a free sample of the full report are available at http://www.giiresearch.com/report/gd244312-medical-devices-contract-research-organizations.html
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a target protein or nucleic acid in a way that is useful for treatment of disease. The process by which molecules are identified for their therapeutic value involves synthesis and analysis of many derivatives of the original leads. There are several steps in the drug discovery process including hit confirmation, lead generation, lead optimization, and other studies. Drug discovery is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will actually yield products that achieve regulatory approval by the Food & Drug Administration (FDA).
Since the last edition of Kalorama’s Report on the outsourcing of discovery of novel compounds in the pharmaceutical industry, the industry has seen dramatic change. Pharmaceutical companies facing cutbacks in R&D budgets and new demands for novel products need to outsource aspects of their operations. Core functions once kept in-house such as the discovery of potential new drugs are now commonly outsourced. Kalorama Information’s Outsourcing in Drug Discovery captures this trend, offering unparalleled coverage of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers in China, India, Russia and Eastern Europe is covered in detail. The report also provides profiles of 23 suppliers, representative of those active in this market.
An Executive Summary of this analysis and a free sample of the full report are available at http://www.giiresearch.com/report/kl241549-outsourcing-drug-discovery-contract-research.html
About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.
Media Contact: Jeremy Palaia, Global Information, Inc., 1-860-674-8796, Press@gii.co.jp
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Global Information, Inc.